Comparable stake leader
Ehud Geller
SEC ownership of REGENTIS BIOMATERIALS LTD.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001912966.
Disclosed value leader
Ehud Geller
Comparable rows
1/6
Latest evidence
09 Jul 2026
- Public ticker
- RGNT on NYSE
- Parsed ownership sources
-
13D/G and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Ehud Geller
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
1 of 6
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Ehud Geller
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
09 Jul 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001912966
- Issuer location
- Or Akiva
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of REGENTIS BIOMATERIALS LTD. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Ehud Geller
Disclosed value leader
Ehud Geller
Comparable rows
1/6
Latest evidence
09 Jul 2026
13D/G
3/4/5
Lead comparable stake: 23%
5 rows are not safely comparable across share classes.
13D/G row: Ehud Geller
Quick read
Ehud Geller leads the comparable SEC ownership view at 23%.
1 of 6 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Ehud Geller's linked filing trail.
Comparable ownership
Top 1
Ehud Geller
23%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 6 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Ehud Geller |
13D/G
3/4/5
Dr. Ehud Geller · Chief Executive Officer, Director
|
23%
|
$8,730,279
1,332,867 shares
|
$0 | 31 Dec 2025 |
| Jeff Dykan |
3/4/5
Director
|
—
mixed-class rows
|
$533,601
167,791 shares
mixed-class rows
|
— | 09 Jul 2026 |
| Pini Ben-Elazar |
3/4/5
Director
|
—
mixed-class rows
|
$526,243
136,979 shares
mixed-class rows
|
— | 09 Jul 2026 |
| Efraim Cohen-Arazi |
3/4/5
Director
|
—
class O/S missing
|
—
24,826 shares
|
— | 09 Jul 2026 |
| Keith Valentine |
3/4/5
Director
|
—
class O/S missing
|
—
24,826 shares
|
— | 09 Jul 2026 |
| Susan PhD Alpert MD |
3/4/5
Director
|
—
class O/S missing
|
—
24,826 shares
|
— | 09 Jul 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 16 Aug 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-9 of 9 reporting-owner rows connected to REGENTIS BIOMATERIALS LTD.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
9
Largest Forms 3/4/5 holder
Jeff Dykan
Net 12M change
$0
Latest report
09 Jul 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Jeff Dykan | Director | $533,601 | Mixed | 09 Jul 2026 | ||
| Pini Ben-Elazar | Director | $526,243 | Mixed | 09 Jul 2026 | ||
| Ori Gon | Chief Financial Officer | Mixed | 18 Mar 2026 | |||
| Susan PhD Alpert MD | Director | Mixed | 09 Jul 2026 | |||
| Arie Gordashnikov | Chief Accounting Officer | Mixed | 18 Mar 2026 | |||
| Ehud Geller | Chief Executive Officer, Director | Mixed | 09 Jul 2026 | |||
| Efraim Cohen-Arazi | Director | Mixed | 09 Jul 2026 | |||
| Galit Reske | Chief Medical Officer | Mixed | 18 Mar 2026 | |||
| Keith Valentine | Director | Mixed | 09 Jul 2026 |
Recent insider transactions for REGENTIS BIOMATERIALS LTD.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Susan PhD Alpert MD | RGNT | Employee Stock Option (Right to Buy) | Award | 24,826 | 24,826 | 09 Jul 2026 | Direct | |||
| Pini Ben-Elazar | RGNT | Employee Stock Option (Right to Buy) | Award | 33,139 | 24,826 | 09 Jul 2026 | Direct | |||
| Keith Valentine | RGNT | Employee Stock Option (Right to Buy) | Award | 24,826 | 24,826 | 09 Jul 2026 | Direct | |||
| Jeff Dykan | RGNT | Employee Stock Option (Right to Buy) | Award | 24,826 | 24,826 | 09 Jul 2026 | Direct | |||
| Jeff Dykan | RGNT | Warrants to purchase ordinary shares | Award | 12,500 | 12,500 | 09 Jul 2026 | Direct | |||
| Ehud Geller | RGNT | Warrants to purchase ordinary shares | Award | 31,250 | 31,250 | 09 Jul 2026 | Direct | |||
| Efraim Cohen-Arazi | RGNT | Employee Stock Option (Right to Buy) | Award | 24,826 | 24,826 | 09 Jul 2026 | Direct |
* marks a reported price that did not pass the local price check.